Loading
A phase 3 trial of Anlotinib, Bevacizumab, CAPOX in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT04854668 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 748 participants enrolled, started 2021-05-27 and due to reach its primary completion in 2024-12-31. Interventions recorded: Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Capecitabine.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Capecitabine, Colorectal cancer.